COMMUNIQUÉS West-GlobeNewswire

-
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
17/04/2024 -
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
17/04/2024 -
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
17/04/2024 -
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
17/04/2024 -
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
17/04/2024 -
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
17/04/2024 -
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
17/04/2024 -
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
17/04/2024 -
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
17/04/2024 -
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
17/04/2024 -
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
17/04/2024 -
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
17/04/2024 -
New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes
17/04/2024 -
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
17/04/2024 -
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
17/04/2024 -
BrainsWay Expands Deep TMS™ Access in Israel Following Significant Increase in Reimbursement Rates
17/04/2024 -
Zylö announces the creation and spinout of Atticus Pharma Inc.
17/04/2024 -
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
17/04/2024 -
Ocean Drive Plastic Surgery Founder Dr. Alan Durkin Appointed VIO Med Spa Chief Medical Officer
17/04/2024
Pages